Premium
iPS Cells in Type 1 Diabetes Research and Treatment
Author(s) -
Maehr R
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.1
Subject(s) - induced pluripotent stem cell , type 1 diabetes , type 2 diabetes , diabetes mellitus , cell type , medicine , clinical pharmacology , cellular differentiation , pharmacology , bioinformatics , computational biology , cell , biology , endocrinology , embryonic stem cell , biochemistry , gene
Induced pluripotent stem (iPS) cells, with their ability to differentiate into every cell type of the body, represent a perfect source for cell‐replacement therapies in type 1 diabetes (T1D). Hence, there is a need to optimize the differentiation protocols to generate fully glucose‐responsive and mature cells. In addition, the use of iPS cells could make possible the generation of patient‐specific disease models that could further our understanding of the root cause of autoimmune diabetes. Clinical Pharmacology & Therapeutics (2011) 89 5, 750–753. doi: 10.1038/clpt.2011.1